US EditionSupreme Court Temporarily Restores Mifepristone Mail Access
Justice Samuel Alito’s stay keeps telehealth and pharmacy access in place as the court reviews emergency appeals from drugmakers and Louisiana.
- The Supreme Court temporarily restored nationwide mail-order access to the abortion drug Mifepristone on May 4, pausing a ruling that required in-person doctor prescriptions until at least May 11 as litigation continues.
- Louisiana challenged the FDA's telehealth prescription rule, arguing that mail delivery of Mifepristone undermines state abortion bans and raises safety concerns.
- Drugmakers and abortion rights advocates criticized the restrictive ruling, emphasizing the drug's FDA-approved safety record since 2000 and calling the legal dispute a disruption to time-sensitive medical care.
- Justice Samuel Alito issued a temporary stay allowing current access rules to continue while the Supreme Court reviews the broader legal disputes and requests briefs to decide next steps.
145 Articles
145 Articles
Supreme Court deals conservatives major setback in war on abortion pill
The US Supreme Court on Monday temporarily restored access to mifepristone, a medication commonly used for abortion and early miscarriage care, through the mail while the justices review a decision requiring it to be dispensed in person by a medical provider.Justice Samuel Alito, who is part of the ...
The U.S. Supreme Court temporarily reinstated, on Monday, the mailing of mifepristone, the pill used in most of the voluntary terminations of pregnancy in the country, suspended last week by an ultra-conservative appeal court. With its historic decision of June 2022, which annulled the federal guarantee of the right to abortion, the conservative Supreme Court returned to the states full freedom to legislate in this area. Since then, about 20 of …
The U.S. Supreme Court re-establishes a federal rule that allows prescribing abortion by telemedicine and providing it by mail.
Coverage Details
Bias Distribution
- 51% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
